Institute of Digestive Disease and Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Cancer. 2013 Mar 15;119(6):1217-26. doi: 10.1002/cncr.27865. Epub 2012 Dec 4.
Previous reports from these authors found that activation of peroxisome proliferator-activated receptor gamma (PPARγ) suppressed hepatocellular carcinoma (HCC). This study sought to identify the molecular target of PPARγ and characterize its antitumor effect in HCC.
Optimal PPARγ binding activity was obtained using the PPARγ agonist rosiglitazone (100 μM) as determined by enzyme-linked immunosorbent assay. Under PPARγ activation, 114 PPARγ downstream targets associated with cancer development were identified by oligonucleotide microarray and Gene Ontology analysis. Among them, Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 (CITED2) was the most prominent PPARγ-bound target, as determined by chromatin immunoprecipitation-polymerase chain reaction.
CITED2 messenger RNA and protein was significantly down-regulated in primary HCCs compared with their adjacent nontumor tissues. PPARγ induced expression of CITED2 in HCC cell lines after adenovirus-PPARγ transduction. The biological function of CITED2 was evaluated by loss- and gain-of-function assays. CITED2 knockdown in the hepatocyte cell line LO2 and HCC cell line Hep3B significantly increased cell viability and clonogenicity, and promoted G1 -S phase transition in both cell lines. In contrast, ectopic expression of CITED2 in HepG2 and BEL7404 HCC cell lines significantly suppressed cell growth. The tumor suppressive effect of CITED2 was associated with up-regulation of cyclin-dependent kinase inhibitors p15(INK4B) , p21(Wat1/Cip1) , p27(Kip1) , antiproliferative regulator interferon alpha 1, proapoptotic mediators including tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), TNFRSF25, caspase-8, granzyme A, and the tumor suppressor gene maspin. CITED2 was also associated with the down-regulation of cell cycle regulator cyclin D1, oncogene telomerase reverse transcriptase, and proinvasion/metastasis gene matrix metallopeptidase 2.
CITED2 is a direct effector of PPARγ for tumor suppression. Cancer 2013. © 2012 American Cancer Society.
作者之前的报告发现过过氧化物酶体增殖物激活受体γ(PPARγ)的激活可以抑制肝细胞癌(HCC)。本研究旨在确定 PPARγ 的分子靶标并描述其在 HCC 中的抗肿瘤作用。
通过酶联免疫吸附试验(ELISA)确定 PPARγ 激动剂罗格列酮(100μM)获得最佳的 PPARγ 结合活性。在 PPARγ 激活下,通过寡核苷酸微阵列和基因本体分析鉴定了 114 个与癌症发展相关的 PPARγ 下游靶标。其中,Cbp/p300 相互作用转录激活因子,富含谷氨酸/天冬氨酸的羧基末端域 2(CITED2)是最突出的 PPARγ 结合靶标,通过染色质免疫沉淀-聚合酶链反应确定。
与相邻非肿瘤组织相比,原发性 HCC 中 CITED2 的信使 RNA 和蛋白表达明显下调。腺病毒-PPARγ 转导后,PPARγ 诱导 HCC 细胞系中 CITED2 的表达。通过缺失和获得功能测定评估 CITED2 的生物学功能。在肝细胞系 LO2 和 HCC 细胞系 Hep3B 中 CITED2 的敲低显着增加了细胞活力和集落形成,并促进了两个细胞系的 G1-S 期转变。相反,在 HepG2 和 BEL7404 HCC 细胞系中外源表达 CITED2 可显着抑制细胞生长。CITED2 的肿瘤抑制作用与细胞周期蛋白依赖性激酶抑制剂 p15(INK4B)、p21(Wat1/Cip1)、p27(Kip1)、增殖调节剂干扰素α 1、包括肿瘤坏死因子受体超家族成员 1A(TNFRSF1A)、TNFRSF25、半胱天冬酶-8、颗粒酶 A 和肿瘤抑制基因 maspin 在内的促凋亡介质的上调有关。CITED2 还与细胞周期调节剂 cyclin D1、致癌基因端粒酶逆转录酶和促侵袭/转移基因基质金属蛋白酶 2 的下调有关。
CITED2 是 PPARγ 抑制肿瘤的直接效应物。癌症 2013。©2012 美国癌症协会。